Project Grant R01CA291848
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $498K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
- Federal Grant Award Summary Duke University's Office of Research Administration received a $395,846 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports research into therapeutic targeting of SMARCAL1 as a synthetic lethal vulnerability in alternative lengthening of telomeres (ALT)-positive cancers, specifically IDH-mutant astrocytomas. The research focuses on...
- Federal Grant Award Summary Duke University received a $411,152 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 5, 2025, with a completion date of August 31, 2027. This research initiative addresses the identification and validation of noncovalent protein interactions associated with mutant KRAS (MKRAS) inhibitors, building upon recent advances in KRAS G12C-targeted therapeutics that have achieved FDA...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Project Grant Award Summary Duke University received a $668,691 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on March 11, 2026, with a completion date of February 28, 2031. The award funds a hierarchical 2x2 factorial randomized controlled trial (RCT) testing two evidence-based interventions designed to improve treatment outcomes and quality of life for older women (age 65+) with hormone receptor-positive breast cancer...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $332,212 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on September 10, 2025, with completion targeted for March 9, 2028. The award supports a research training and career development initiative focused on investigating sex hormone signaling in hepatocellular carcinoma (HCC). The project deliverables include comprehensive...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $1.88 million Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded on September 23, 2025, with a completion date of August 31, 2029. The grant funds fundamental research to integrate genome-wide association study (GWAS) data with single-cell omics technologies to identify cellular effectors of glioblastoma predisposition. This research initiative...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $1.54M project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research activities focused on assessing prognoses and validating surrogate endpoints for clinical outcomes in metastatic hormone-sensitive prostate cancer. This research initiative aligns with the Defense...
- Federal Project Grant Award Summary Yale University received a $192,564 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, through August 31, 2028. The award supports research focused on developing a novel dual-target PROTAC (Proteolysis Targeting Chimera)-based protein degrader to address therapy resistance in metastatic castration-resistant prostate cancer (MCRPC). The project leverages a newly developed...
- The federal Project Grant award of $481,158.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) enables Duke University to conduct research aimed at "Blocking Glutamine Utilization in Advanced and Therapy-Resistant Prostate Cancer." The award supports a two-year project from June 1, 2024 to May 31, 2026 to expand the frontiers of scientific knowledge and apply it to address a critical medical challenge facing military service...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $135,993 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective December 1, 2025, with completion anticipated by May 31, 2027. The award funds investigative research examining the role of the Abelson (ABL) kinase-regulated hypoxia inducible factor-1 alpha (HIF-1A) and transcriptional co-activator with PDZ-binding motif (TAZ) signaling...